Inhibition of mucus secretion by niclosamide and benzbromarone in airways and intestine

Jiraporn Ousingsawat(University of Regensburg), Karl Kunzelmann(University of Regensburg), Ursula Seidler(Medizinische Hochschule Hannover), Raquel Centeio(University of Lisbon), Rainer Schreiber(University of Regensburg), Dorothee Römermann(Medizinische Hochschule Hannover), Alexandra McCarron(The University of Adelaide), Nicole Reyne(Women's and Children's Hospital), Patricia Cmielewski(Women's and Children's Hospital), Gabriella diStefano(Medizinische Hochschule Hannover), Martin Donnelley(The University of Adelaide)
Scientific Reports
January 17, 2024
10.1038/s41598-024-51397-w
Cited by 10

Related Papers

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity
|PLoS ONE|2007|478
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
|The Lancet|2021|452
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2017|449
Intestinal Secretory Defects and Dwarfism in Mice Lacking cGMP-Dependent Protein Kinase II
|Science|1996|409